Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) outlined a 2027 timeline for pivotal hypertension trial data and potential FDA submissions as the company and partner Medtronic advance …
Orchestra BioMed Advances FDA Path for Hypertension Device Read More
MALVERN, PA — TELA Bio, Inc. (Nasdaq: TELA) reported modest first-quarter revenue growth as accelerating European sales helped offset slower product mix trends in the United States.
TELA Bio Expands Europe Sales as U.S. Growth Slows Read More
WILMINGTON, DE — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) reported that it has secured regulatory clearance in 16 countries for its Phase 3 pulmonary arterial hypertension study, marking a key step …
Inhibikase Gains EU Clearance for Global PAH Trial Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported higher first-quarter revenue and accelerating demand for its YCANTH treatment as the company advances late-stage clinical trials that could significantly …
Verrica Expands YCANTH Sales as Wart Trials Advance Read More
WILMINGTON, DE — Prelude Therapeutics (Nasdaq: PRLD) has begun patient enrollment in a Phase 1 study of its lead blood cancer drug candidate while advancing additional oncology programs targeting breast …
Prelude Therapeutics Advances Lead Blood Cancer Program as Cash Runway Extends Into 2028 Read More
CHESTERBROOK, PA — Vishay Precision Group (NYSE: VPG) reported higher first-quarter revenue and a sharp increase in bookings as demand strengthened across semiconductor equipment, aerospace, defense and industrial markets.
VPG Orders Top $100 Million as Industrial Demand Rebounds Read More
PHILADELPHIA, PA — Enviri Corporation (NYSE: NVRI) reported a first-quarter loss from continuing operations as the company moves toward the planned sale of its Clean Earth business and the spin-off …
Enviri Reaffirms Outlook Ahead of Planned Breakup Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma (Nasdaq: AVBP) reported first-quarter results as the company advanced late-stage testing of its lung cancer therapy firmonertinib and moved two antibody-drug conjugate programs closer …
ArriVent BioPharma Advances Lung Cancer Program, ADC Pipeline Read More
VALLEY FORGE, PA — UGI Corporation (NYSE: UGI) lowered its fiscal 2026 adjusted earnings guidance after reporting softer year-to-date earnings, reflecting the impact of growth investment timing and ongoing operational …
UGI Cuts Earnings Outlook as Growth Investments Weigh Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported 17% first-quarter revenue growth for its narcolepsy drug WAKIX while advancing patent litigation, new formulations and pipeline programs aimed …
Harmony Revenue Rises as WAKIX Franchise Expands Read More